Assessment of Longterm Outcomes of Ticagrelor in Coronary Artery Disease Patients

Abstract

Objective: The mainstay of antiplatelet medication for the treatment of coronary artery disease, especially acute coronary syndrome and post-percutaneous procedures, is ticagrelor. In order to show that ticagrelor is safe and effective in lowering major adverse cardiac events (MACEs) such as MI, stroke, and cardiovascular death, as well as its safety concerns regarding bleeding risk and side effects like breathing difficulties and significant bradycardia, the study aims to evaluate the long-term outcomes of ticagrelor in patients with coronary artery disease [CAD]. Methodology: One hundred and twenty people took part in the prospective observational study. Researchers looked examined the clinical outcomes following long-term medication usage and the incidence of significant adverse cardiac events in patients with coronary artery disease (including ACS, history of MI, or post PCI treated with ticagrelor). Results: Our study primarily focused on age, gender, and individuals with a history of coronary artery disease. The purpose of the study was to evaluate the long-term effects of ticagrelor on coronary artery disease in 120 individuals, with 84 males (70%) and 36 females (30%) making up the study population.People with lifestyle variables, such as smoking and alcohol use, as well as comorbidities, such as diabetes mellitus and hypertension, were part of the study population. According to the results of the research, the most common side effects of the medicine during long-term usage were dyspnea (47.5% of patients), bleeding (29.2% of patients), bradycardia (8.3% of patients), and significant adverse cardiac events (29.2% of patients). Conclusion: Patients with coronary artery disease who took ticagrelor for an extended period of time had a markedly lower risk of death from any cause and a marked decrease in the occurrence of major adverse cardiovascular events (MACE).A higher quality of life in terms of one's health was also linked to the medicine. Be cautious, nevertheless, because there is an increased risk of bleeding during treatment, especially little bleeding and dyspnea. Patients with coronary artery disease (CAD) have an attractive alternative for long-term antiplatelet treatment with ticagrelor, which may improve clinical results and quality of life.